1632-74-2

Basic information

• Product Name: 3,6-Dimethyl Pyridazine
• Synonyms: 3,6-Dimethyl Pyridazine;Pyridazine, 3,6-diMethyl-;3,6-dimethylpyridazin
• CAS NO: 1632-74-2
• Molecular Formula: C₆H₈N₂
• Molecular Weight: 108
• Mol File: 1632-74-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 32-33℃
• Boiling Point: 228℃
• Flash Point: 100℃
• Appearance: /
• Density: 0.997
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.04±0.10(Predicted)
• CAS DataBase Reference: 3,6-Dimethyl Pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-Dimethyl Pyridazine(1632-74-2)
• EPA Substance Registry System: 3,6-Dimethyl Pyridazine(1632-74-2)

Safety Data

• Hazardous Substances Data: 1632-74-2(Hazardous Substances Data)

Usage

General Description

3,6-Dimethyl pyridazine is a chemical compound with the molecular formula C6H8N2. It is a heterocyclic and aromatic compound that consists of a six-membered ring containing two nitrogen atoms and two methyl groups at positions 3 and 6. This chemical is commonly used as a building block in organic synthesis and pharmaceutical research. It has been investigated for its potential applications in the development of new drugs and agrochemicals due to its diverse and useful properties. Additionally, its structure and reactivity make it a valuable intermediate in the production of various other chemicals and materials.

Upstream product

• 3031-66-1 3-hexyn-2,5-diol 
• 14331-54-5 2,4-dimethylpyrimidine 
• 5910-89-4 2,3-dimethylpyrazine 
• 17417-44-6 NSC 166900 
• 40838-54-8 3,6-Bis-(chlormethyl)-4-oxo-1,4-dihydropyridazin 
• 17417-53-7 3,6-dimethyl-1H-pyridazin-4-one 
• 625-86-5 2,5-dimethylfuran 
• 7647-01-0 hydrogenchloride 
• 55643-61-3 3,6-dimethyl-pyridazine-4,5-dicarboxylic acid 
• 76473-32-0 C₉H₁₃N₃O₂ 
• 110-13-4 2,5-hexanedione 
• 61892-85-1 3-hydroxyhexane-2,5-dione 
• 57542-36-6 3,6-dimethyl-2,3,4,5-tetrahydro-pyridazine-3-carbonitrile 
• 18091-25-3 2,5-dimethoxy-2,5-dimethyl-2,5-dihydro-furan 

Downstream Products

• 1417826-25-5 C₁₈H₁₅F₃N₂O₂ 
• 57266-70-3 pyridazine-3,6-dicarboxylic acid 
• 27914-99-4 3,6-dimethylpyridazine 1-oxide 
• 19194-90-2 3,6-dimethylpyridazine-N,N-dioxide 
• 1407189-90-5 C₂₀H₂₀F₃N₃O₂ 
• 1239233-49-8 dimethyl 2-[[4-[(4-ethynylphenyl)ethynyl]phenyl]ethynyl]-2',4'a-dimethylspiro[9H-fluorene-9,5'(4'aH)-pyrrolo[1,2-b]pyridazine]-6',7'-dicarboxylate 
• 1239233-48-7 dimethyl 2-[(4-ethynylphenyl)ethynyl]-2',4'a-dimethylspiro[9H-fluorene-9,5'(4'aH)-pyrrolo[1,2-b]pyridazine]-6',7'-dicarboxylate 
• 1210518-81-2 dimethyl 2,7-bis((4-(5-(4-tert-butylphenyl)-1,3,4-oxadiazol-2-yl)phenyl)buta-1,3-diynyl)-2',4a'-dimethyl-4a'H-spiro[fluorene-9,5'-pyrrolo[1,2-b]pyridazine]-6',7'-dicarboxylate 
• 1210518-76-5 dimethyl 2-((4-(5-(4-tert-butylphenyl)-1,3,4-oxadiazol-2-yl)phenyl)buta-1,3-diynyl)-2',4a'-dimethyl-4a'H-spiro[fluorene-9,5'-pyrrolo[1,2-b]pyridazine]-6',7'-dicarboxylate 
• 1210518-79-8 dimethyl 2,7-bis((4-(5-(4-tert-butylphenyl)-1,3,4-oxadiazol-2-yl)phenyl)ethynyl)-2',4a'-dimethyl-4a'H-spiro[fluorene-9,5'-pyrrolo[1,2-b]pyridazine]-6',7'-dicarboxylate 
• 1210518-75-4 dimethyl 2-((4-(5-(4-tert-butylphenyl)-1,3,4-oxadiazol-2-yl)phenyl)ethynyl)-2',4a'-dimethyl-4a'H-spiro[fluorene-9,5'-pyrrolo[1,2-b]pyridazine]-6',7'-dicarboxylate 
• 1133809-78-5 dimethyl 2,7-bis((4-ethynylphenyl)ethynyl)-2',4a'-dimethyl-4a'H-spiro[fluorene-9,5'-pyrrolo[1,2-b]pyridazine]-6',7'-dicarboxylate 
• 1041777-96-1 (E,E)-3,6-bis[2-(4-methoxyphenyl)vinyl]pyridazine 
• 1041778-12-4 (E,E)-3,6-bis[2-(4-octyloxyphenyl)vinyl]pyridazine 

Relevant articles and documents

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Compounds for treating spinal muscular atrophy

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

Synthesis and structure of dilead(II) and dimanganese(II) complexes of macrocycles derived from 3,6-diformylpyridazine

An improved synthesis of 3,6-diformylpyridazine I has been elaborated. The macrocyclic complexes Pb2L1(ClO4)4 1 and [Pb2L2][ClO4]4 2 were prepared from this precursor, 1,3-diaminopropane and lead(II) perchlorate in 1:1:1 and 2:2:1 ratios respectively. The ability of lead(II) perchlorate to template the formation of the two macrocycle ring sizes, L1 = (2 + 2) and L2 = (4 + 4), simply by alteration of the reagent ratio is unprecedented. Transmetallation of 1 or 2 with manganese(II) perchlorate and an excess of sodium thiocyanate led to the formation of [Mn2L1(NCS)4] 3. Single-crystal X-ray analyses of 2 and 3 revealed that on transmetallation a ring contraction, (4 + 4) to (2 + 2), occurs. The two manganese(II) ions have irregular geometries and are inequivalent; one is six- whilst the other is seven-co-ordinate. Unusual single-atom > NCS bridging of the manganese ions occurs.